New Data at ESMO 2019 for Merck Highlight Focused Clinical Dev...
DARMSTADT, Germany, Sept.. 23, 2019, /PRNewswire-AsiaNet/-- Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts #BAVENCIO(R)(avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX(R)(cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR...
Authors: LATEST ASIANET NEWS RELEASES